From experience comes our best insightsThe history of Italfarmacia kicked off in 1995 with a specific goal: to develop and manufacture innovative products capable of ensuring, in addition to proven efficacy, original formulations to meet different needs in the health and wellness area. The project is ambitious, but the company’s founder, Mario Marchetti, can draw on his extensive experience in the drug.
Looking at things from above to see fartherThe innate inclination toward research and the many experiences gained in the pharmaceutical field have been the dominant factor for Italfarmacia from the beginning, which, thanks to its ability to take a broad view of the world of health, has been able to grasp the still unmet wellness demands in advance. The ability of Italfarmacia’s management was and is therefore to be able to translate these signals into concrete stimuli to investigate and, where possible, find the most appropriate solutions through the development of products that meet the various needs.
Anticipating market needs interests us as much as meeting themIntuiting and catching in advance every signal coming from the changed health needs and new realities of care to be offered to the physician, and consequently to its Partners, is the priority in all Italfarmacia’s development programs. Combining knowledge already acquired, but applying it in entirely new ways, to the point of arriving at new original, effective, and well-tolerated therapies is the challenge to achieve the most prestigious goals, inescapable with worldwide patent recognition.
Translating our expertise into lasting relationships of trust
Doing wide-ranging research with commitment, rigor, knowledge of the subject matter, and being able to concretize study hypotheses through the realization of useful and safety-guaranteed products has been the key to Italfarmacia’s success from the very beginning. Major pharmaceutical companies, interested in the many therapeutic options gradually developed by Italfarmacia, have entered into collaborations through exclusive licensing agreements in countries of specific interest.